메뉴 건너뛰기




Volumn 7, Issue , 2013, Pages 1067-1075

Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review

Author keywords

Adherence; Efficacy; Hepatitis C virus; People who inject drugs; Treatment uptake

Indexed keywords

BOCEPREVIR; OPIATE; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

EID: 84886028561     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S49113     Document Type: Review
Times cited : (50)

References (105)
  • 1
    • 84876149257 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
    • Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-1342.
    • (2013) Hepatology. , vol.57 , Issue.4 , pp. 1333-1342
    • Mohd Hanafiah, K.1    Groeger, J.2    Flaxman, A.D.3    Wiersma, S.T.4
  • 2
    • 59149083248 scopus 로고    scopus 로고
    • The history of the "natural history" of hepatitis C (1968-2009)
    • Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99.
    • (2009) Liver Int. , vol.29 , Issue.SUPPL. 1 , pp. 89-99
    • Seeff, L.B.1
  • 3
    • 10744225097 scopus 로고    scopus 로고
    • Global burden of disease (GBD) for hepatitis C
    • World Health Organization
    • World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20-29.
    • (2004) J Clin Pharmacol. , vol.44 , Issue.1 , pp. 20-29
  • 4
    • 34250679750 scopus 로고    scopus 로고
    • Epidemiology of hepatitis C virus infection
    • Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-2441.
    • (2007) World J Gastroenterol. , vol.13 , Issue.17 , pp. 2436-2441
    • Alter, M.J.1
  • 5
    • 84455209550 scopus 로고    scopus 로고
    • HCV routes of transmission: What goes around comes around
    • Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis. 2011;31(4):340-346.
    • (2011) Semin Liver Dis. , vol.31 , Issue.4 , pp. 340-346
    • Alter, M.J.1
  • 6
    • 79953168791 scopus 로고    scopus 로고
    • Virová hepatitida C. [Hepatitis C virus]
    • Czech
    • Urbánek P. Virová hepatitida C. [Hepatitis C virus]. Adiktologie. 2010;10(2):102-109. Czech.
    • (2010) Adiktologie. , vol.10 , Issue.2 , pp. 102-109
    • Urbánek, P.1
  • 7
    • 78751610017 scopus 로고    scopus 로고
    • Hidden hazards of HCV transmission
    • Czech
    • Pondé RA. Hidden hazards of HCV transmission. Med Microbiol Immunol. 2011;200(1):7-11. Czech.
    • (2011) Med Microbiol Immunol. , vol.200 , Issue.1 , pp. 7-11
    • Pondé, R.A.1
  • 8
    • 34548489173 scopus 로고    scopus 로고
    • Global estimates of prevalence of HCV infection among injecting drug users
    • Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-358.
    • (2007) Int J Drug Policy. , vol.18 , Issue.5 , pp. 352-358
    • Aceijas, C.1    Rhodes, T.2
  • 9
    • 80051676859 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews
    • Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583.
    • (2011) Lancet. , vol.378 , Issue.9791 , pp. 571-583
    • Nelson, P.K.1    Mathers, B.M.2    Cowie, B.3
  • 10
    • 33845438736 scopus 로고    scopus 로고
    • European Monitoring Centre for Drugs and Drug Addiction; Annual Report 2012., Luxembourg: Publications Office of the European Union, Available from:, Accessed September 1, 2013
    • European Monitoring Centre for Drugs and Drug Addiction; Annual Report 2012. The State of the Drugs Problem in Europe. Luxembourg: Publications Office of the European Union; 2012. Available from: http://www.emcdda.europa.eu/...cfm/att_190854_EN_TDAC12001ENC_.pdf. Accessed September 1, 2013.
    • (2012) The State of the Drugs Problem in Europe
  • 11
    • 33748114343 scopus 로고    scopus 로고
    • The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
    • Perz JF, Armstrong GL, Farrington LA, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4): 529-538.
    • (2006) J Hepatol. , vol.45 , Issue.4 , pp. 529-538
    • Perz, J.F.1    Armstrong, G.L.2    Farrington, L.A.3    Hutin, Y.4    Bell, B.5
  • 12
    • 43349090325 scopus 로고    scopus 로고
    • Limited uptake of hepatitis C treatment among injection drug users
    • Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126-133.
    • (2008) J Community Health. , vol.33 , Issue.3 , pp. 126-133
    • Mehta, S.H.1    Genberg, B.L.2    Astemborski, J.3
  • 13
    • 63549098520 scopus 로고    scopus 로고
    • Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents
    • Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16(5):352-358.
    • (2009) J Viral Hepat. , vol.16 , Issue.5 , pp. 352-358
    • Grebely, J.1    Raffa, J.D.2    Lai, C.3
  • 14
    • 20144388125 scopus 로고    scopus 로고
    • Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users
    • Strathdee S, Latka M, Campbell J, et al. Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005;40 Suppl 5:S304-S312.
    • (2005) Clin Infect Dis. , vol.40 , Issue.SUPPL. 5
    • Strathdee, S.1    Latka, M.2    Campbell, J.3
  • 15
    • 84859650825 scopus 로고    scopus 로고
    • Sydney, Australia: Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Available from:, Accessed September 1, 2013
    • Iversen J, Topp LJ, Maher L. Australian NSP Survey National Data Report 1995-2010. Sydney, Australia: Faculty of Medicine, The Kirby Institute for Infection and Immunity in Society, University of New South Wales; 2011. Available from: http://www.kirby.unsw.edu.au/node/201260281. Accessed September 1, 2013.
    • (2011) Australian NSP Survey National Data Report 1995-2010
    • Iversen, J.1    Topp, L.J.2    Maher, L.3
  • 16
    • 33644875265 scopus 로고    scopus 로고
    • Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies
    • Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34-41.
    • (2006) J Viral Hepat. , vol.13 , Issue.1 , pp. 34-41
    • Micallef, J.M.1    Kaldor, J.M.2    Dore, G.J.3
  • 17
    • 43549109840 scopus 로고    scopus 로고
    • Acute hepatitis C: A systematic review
    • Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103(5):1283-1297.
    • (2008) Am J Gastroenterol. , vol.103 , Issue.5 , pp. 1283-1297
    • Kamal, S.M.1
  • 18
    • 81055140960 scopus 로고    scopus 로고
    • Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort
    • van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011;6(11):e27555.
    • (2011) PLoS One. , vol.6 , Issue.11
    • van den Berg, C.H.1    Grady, B.P.2    Schinkel, J.3
  • 19
    • 84860297348 scopus 로고    scopus 로고
    • International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine
    • Grebely J, Prins M, Hellard M, et al. International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5): 408-414.
    • (2012) Lancet Infect Dis. , vol.12 , Issue.5 , pp. 408-414
    • Grebely, J.1    Prins, M.2    Hellard, M.3
  • 20
    • 78650806908 scopus 로고    scopus 로고
    • Future hepatitis C virus treatment: Interferon-sparing combinations
    • Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31 Suppl 1:62-67.
    • (2011) Liver Int. , vol.31 , Issue.SUPPL. 1 , pp. 62-67
    • Gane, E.1
  • 21
    • 75149163334 scopus 로고    scopus 로고
    • Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
    • Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-521.
    • (2010) Gastroenterology. , vol.138 , Issue.2 , pp. 513-521
    • Davis, G.L.1    Alter, M.J.2    El-Serag, H.3    Poynard, T.4    Jennings, L.W.5
  • 22
    • 77955305804 scopus 로고    scopus 로고
    • The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression
    • John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010;53(2): 245-251.
    • (2010) J Hepatol. , vol.53 , Issue.2 , pp. 245-251
    • John-Baptiste, A.1    Krahn, M.2    Heathcote, J.3    Laporte, A.4    Tomlinson, G.5
  • 23
    • 35148826147 scopus 로고    scopus 로고
    • Natural history of chronic hepatitis C virus infection
    • Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis. 2007;39 Suppl 1:S4-S7.
    • (2007) Dig Liver Dis. , vol.39 , Issue.SUPPL. 1
    • Ascione, A.1    Tartaglione, T.2    Di Costanzo, G.G.3
  • 24
    • 84455182283 scopus 로고    scopus 로고
    • What is killing people with hepatitis C virus infection?
    • Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31(4):331-339.
    • (2011) Semin Liver Dis. , vol.31 , Issue.4 , pp. 331-339
    • Grebely, J.1    Dore, G.J.2
  • 25
    • 0034120427 scopus 로고    scopus 로고
    • Clinical significance of hepatitis C virus genotypes
    • Nizar NZ. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13(2):223-235.
    • (2000) Clin Microbiol Rev. , vol.13 , Issue.2 , pp. 223-235
    • Nizar, N.Z.1
  • 26
    • 0030338551 scopus 로고    scopus 로고
    • Hepatitis C virus: Biological and clinical consequences of genetic heterogeneity
    • Cooreman MP, Schoondermark-Van de Ven EM. Hepatitis C virus: biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol Suppl. 1996;218:106-115.
    • (1996) Scand J Gastroenterol , vol.218 , Issue.SUPPL. , pp. 106-115
    • Cooreman, M.P.1    Schoondermark-Van de Ven, E.M.2
  • 27
    • 0031627537 scopus 로고    scopus 로고
    • Genomic subtypes of hepatitis C virus: Epidemiology, diagnosis and clinical consequences
    • French
    • Nousbaum JB. Genomic subtypes of hepatitis C virus: epidemiology, diagnosis and clinical consequences. Bull Soc Pathol Exot. 1998;91(1): 29-33. French.
    • (1998) Bull Soc Pathol Exot. , vol.91 , Issue.1 , pp. 29-33
    • Nousbaum, J.B.1
  • 28
    • 84855215941 scopus 로고    scopus 로고
    • 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines
    • European Association of the Study of the Liver
    • European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8.
    • (2012) Liver Int. , vol.32 , Issue.SUPPL. 1 , pp. 2-8
  • 29
    • 35448974936 scopus 로고    scopus 로고
    • Antiviral therapy: Chronic hepatitis C
    • Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat. 2007;14 Suppl 1:82-88.
    • (2007) J Viral Hepat. , vol.14 , Issue.SUPPL. 1 , pp. 82-88
    • Heathcote, E.J.1
  • 30
    • 79959478969 scopus 로고    scopus 로고
    • Clinical practice. Chronic hepatitis C infection
    • Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-2438.
    • (2011) N Engl J Med. , vol.364 , Issue.25 , pp. 2429-2438
    • Rosen, H.R.1
  • 31
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44(1):97-103.
    • (2006) J Hepatol. , vol.44 , Issue.1 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3
  • 32
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    • Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43(5):954-960.
    • (2006) Hepatology. , vol.43 , Issue.5 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3
  • 33
    • 33746564989 scopus 로고    scopus 로고
    • Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
    • Sanchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131(2):451-460.
    • (2006) Gastroenterology. , vol.131 , Issue.2 , pp. 451-460
    • Sanchez-Tapias, J.M.1    Diago, M.2    Escartín, P.3
  • 34
    • 48749099989 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 with rapid virological response
    • Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 with rapid virological response. Gastroenterology. 2008;135(2):451-458.
    • (2008) Gastroenterology. , vol.135 , Issue.2 , pp. 451-458
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3
  • 35
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepattis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepattis C virus infection. N Engl J Med. 2002;347(13):975-982.
    • (2002) N Engl J Med. , vol.347 , Issue.13 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 36
    • 67650480397 scopus 로고    scopus 로고
    • Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection
    • Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051-1055.
    • (2009) Liver Int. , vol.29 , Issue.7 , pp. 1051-1055
    • Alvarez-Uria, G.1    Day, J.N.2    Nasir, A.J.3    Russell, S.K.4    Vilar, F.J.5
  • 37
    • 69949160228 scopus 로고    scopus 로고
    • Incidence of hepatitis C in drug injectors: The role of homelessness, opiate substitution treatment, equipment sharing, and community size
    • Craine N, Hickman M, Parry JV, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137(9):1255-1265.
    • (2009) Epidemiol Infect. , vol.137 , Issue.9 , pp. 1255-1265
    • Craine, N.1    Hickman, M.2    Parry, J.V.3
  • 39
    • 79957930147 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs
    • Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74-83.
    • (2011) J Infect Dis. , vol.204 , Issue.1 , pp. 74-83
    • Hagan, H.1    Pouget, E.R.2    Des Jarlais, D.C.3
  • 40
    • 80053581086 scopus 로고    scopus 로고
    • The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence
    • Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-1988.
    • (2011) Addiction. , vol.106 , Issue.11 , pp. 1978-1988
    • Turner, K.M.1    Hutchinson, S.2    Vickerman, P.3
  • 41
    • 84861224989 scopus 로고    scopus 로고
    • Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-implications for intervention impact
    • Vickerman P, Martin NK, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-implications for intervention impact. Drug Alcohol Depend. 2012;123(1-3):122-131.
    • (2012) Drug Alcohol Depend. , vol.123 , Issue.1-3 , pp. 122-131
    • Vickerman, P.1    Martin, N.K.2    Hickman, M.3
  • 42
    • 84867206056 scopus 로고    scopus 로고
    • Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings
    • Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984-1995.
    • (2012) Addiction. , vol.107 , Issue.11 , pp. 1984-1995
    • Vickerman, P.1    Martin, N.2    Turner, K.3    Hickman, M.4
  • 43
    • 79956066416 scopus 로고    scopus 로고
    • Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility
    • Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-1144.
    • (2011) J Hepatol. , vol.54 , Issue.6 , pp. 1137-1144
    • Martin, N.K.1    Vickerman, P.2    Foster, G.R.3    Hutchinson, S.J.4    Goldberg, D.J.5    Hickman, M.6
  • 44
    • 84884365834 scopus 로고    scopus 로고
    • Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements
    • June 27, [Epub ahead of print.]
    • Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. June 27, 2013. [Epub ahead of print.]
    • (2013) Clin Infect Dis.
    • Grebely, J.1    Matthews, G.V.2    Lloyd, A.R.3    Dore, G.J.4
  • 45
    • 79251532744 scopus 로고    scopus 로고
    • Mathematical modelling of hepatitis C treatment for injecting drug users
    • Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011;274(1): 58-66.
    • (2011) J Theor Biol. , vol.274 , Issue.1 , pp. 58-66
    • Martin, N.K.1    Vickerman, P.2    Hickman, M.3
  • 46
    • 78651469588 scopus 로고    scopus 로고
    • Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere
    • Vickerman P, Martin N, Hickman M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2010;113(2-3):83-85.
    • (2010) Drug Alcohol Depend. , vol.113 , Issue.2-3 , pp. 83-85
    • Vickerman, P.1    Martin, N.2    Hickman, M.3
  • 47
    • 77954658245 scopus 로고    scopus 로고
    • Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs
    • Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010;110(3):228-233.
    • (2010) Drug Alcohol Depend. , vol.110 , Issue.3 , pp. 228-233
    • Zeiler, I.1    Langlands, T.2    Murray, J.M.3    Ritter, A.4
  • 48
    • 84155180685 scopus 로고    scopus 로고
    • Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
    • Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-57.
    • (2012) Hepatology. , vol.55 , Issue.1 , pp. 49-57
    • Martin, N.K.1    Vickerman, P.2    Miners, A.3
  • 49
    • 33947106652 scopus 로고    scopus 로고
    • Referral for chronic hepatitis C treatment from a drug dependency treatment setting
    • Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007;88(1):49-53.
    • (2007) Drug Alcohol Depend. , vol.88 , Issue.1 , pp. 49-53
    • Hallinan, R.1    Byrne, A.2    Agho, K.3    Dore, G.J.4
  • 50
    • 78650773812 scopus 로고    scopus 로고
    • Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project
    • Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23(1):23-31.
    • (2011) Eur J Gastroenterol Hepatol. , vol.23 , Issue.1 , pp. 23-31
    • Lindenburg, C.E.1    Lambers, F.A.2    Urbanus, A.T.3
  • 51
    • 76649140825 scopus 로고    scopus 로고
    • Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support
    • Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270-277.
    • (2010) Eur J Gastroenterol Hepatol. , vol.22 , Issue.3 , pp. 270-277
    • Grebely, J.1    Knight, E.2    Genoway, K.A.3
  • 52
    • 77954413120 scopus 로고    scopus 로고
    • Successful integration of hepatitis C evaluation and treatment services with methadone maintenance
    • Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1):20-26.
    • (2010) J Addict Med. , vol.4 , Issue.1 , pp. 20-26
    • Harris Jr., K.A.1    Arnsten, J.H.2    Litwin, A.H.3
  • 53
    • 77649182326 scopus 로고    scopus 로고
    • Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
    • Grebely J, Petoumenos K, Matthews GV, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend. 2010;107(2-3):244-249.
    • (2010) Drug Alcohol Depend. , vol.107 , Issue.2-3 , pp. 244-249
    • Grebely, J.1    Petoumenos, K.2    Matthews, G.V.3
  • 54
    • 84870793129 scopus 로고    scopus 로고
    • Referral of intravenous drug users for antiviral treatment: Effectiveness of hepatitis C case-finding programmes
    • Gazdag G, Horváth G, Szabó O, Ungvari GS. Referral of intravenous drug users for antiviral treatment: effectiveness of hepatitis C case-finding programmes. Cent Eur J Public Health. 2012;20(3):223-225.
    • (2012) Cent Eur J Public Health. , vol.20 , Issue.3 , pp. 223-225
    • Gazdag, G.1    Horváth, G.2    Szabó, O.3    Ungvari, G.S.4
  • 55
    • 83655165142 scopus 로고    scopus 로고
    • Motivácia na liečbu hepatitídy C u užívatelóv psychoaktívnych látok. [Motivation for treatment of HCV infection among drug users]
    • Slovak
    • Slezáková S, Okruhlica L. Motivácia na liečbu hepatitídy C u užívatelóv psychoaktívnych látok. [Motivation for treatment of HCV infection among drug users]. Adiktologie. 2011;11(3):142-146. Slovak.
    • (2011) Adiktologie. , vol.11 , Issue.3 , pp. 142-146
    • Slezáková, S.1    Okruhlica, L.2
  • 56
    • 34548536278 scopus 로고    scopus 로고
    • Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection
    • Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18(5): 437-443.
    • (2007) Int J Drug Policy. , vol.18 , Issue.5 , pp. 437-443
    • Grebely, J.1    Genoway, K.2    Khara, M.3
  • 57
    • 34548508918 scopus 로고    scopus 로고
    • The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection
    • Hopwood M, Treloar C. The drugs that dare not speak their name: injecting and other illicit drug use during treatment for hepatitis C infection. Int J Drug Policy. 2007;18(5):374-380.
    • (2007) Int J Drug Policy. , vol.18 , Issue.5 , pp. 374-380
    • Hopwood, M.1    Treloar, C.2
  • 58
    • 77957988312 scopus 로고    scopus 로고
    • "We fear the police, and the police fear us": Structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine
    • Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. "We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305-1313.
    • (2010) AIDS Care. , vol.22 , Issue.11 , pp. 1305-1313
    • Mimiaga, M.J.1    Safren, S.A.2    Dvoryak, S.3    Reisner, S.L.4    Needle, R.5    Woody, G.6
  • 59
    • 77951800161 scopus 로고    scopus 로고
    • Policing drug users in Russia: Risk, fear, and structural violence
    • Sarang A, Rhodes T, Sheon N, Page K. Policing drug users in Russia: risk, fear, and structural violence. Subst Use Misuse. 2010;45(6):813-864.
    • (2010) Subst Use Misuse. , vol.45 , Issue.6 , pp. 813-864
    • Sarang, A.1    Rhodes, T.2    Sheon, N.3    Page, K.4
  • 60
    • 84859815932 scopus 로고    scopus 로고
    • Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision
    • Cooper CL, Giordano C, Mackie D, Mills EJ. Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision. Ther Clin Risk Manag. 2010;6:207-212.
    • (2010) Ther Clin Risk Manag. , vol.6 , pp. 207-212
    • Cooper, C.L.1    Giordano, C.2    McKie, D.3    Mills, E.J.4
  • 61
    • 84873586783 scopus 로고    scopus 로고
    • Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels
    • Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:S19-S25.
    • (2013) J Infect Dis. , vol.207 , Issue.SUPPL. 1
    • Grebely, J.1    Oser, M.2    Taylor, L.E.3    Dore, G.J.4
  • 62
    • 84856267331 scopus 로고    scopus 로고
    • Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus
    • Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011;17(9):685-694.
    • (2011) J Manag Care Pharm. , vol.17 , Issue.9 , pp. 685-694
    • Tungol, A.1    Rademacher, K.2    Schafer, J.A.3
  • 63
    • 84865414920 scopus 로고    scopus 로고
    • New pharmacotherapy for hepatitis C
    • Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clin Pharmacol Ther. 2012;92(3):294-305.
    • (2012) Clin Pharmacol Ther. , vol.92 , Issue.3 , pp. 294-305
    • Assis, D.N.1    Lim, J.K.2
  • 64
    • 84886046576 scopus 로고    scopus 로고
    • New agents for hepatitis C and the challenges in treating co-infected patients
    • Rockstroh J. New agents for hepatitis C and the challenges in treating co-infected patients. J Int AIDS Soc. 2012;15(6):18115.
    • (2012) J Int AIDS Soc. , vol.15 , Issue.6 , pp. 18115
    • Rockstroh, J.1
  • 65
    • 33748584922 scopus 로고    scopus 로고
    • Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
    • Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006;18(10):1057-1063.
    • (2006) Eur J Gastroenterol Hepatol. , vol.18 , Issue.10 , pp. 1057-1063
    • Sylvestre, D.L.1    Clements, B.J.2    Malibu, Y.3
  • 66
    • 79955871966 scopus 로고    scopus 로고
    • Physicianś attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada
    • Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicianś attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol. 2011;25(3):135-139.
    • (2011) Can J Gastroenterol. , vol.25 , Issue.3 , pp. 135-139
    • Myles, A.1    Mugford, G.J.2    Zhao, J.3    Krahn, M.4    Wang, P.P.5
  • 67
    • 35248887678 scopus 로고    scopus 로고
    • Hepatitis C management by addiction medicine physicians: Results from a national survey
    • Litwin AH, Kunins HV, Berg KM, et al. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat. 2007;33(1):99-105.
    • (2007) J Subst Abuse Treat. , vol.33 , Issue.1 , pp. 99-105
    • Litwin, A.H.1    Kunins, H.V.2    Berg, K.M.3
  • 68
    • 84864243591 scopus 로고    scopus 로고
    • Léčba VHC u injekčních uživatelů drog v ČR-průzkum mezi centry pro léčbu virových hepatitid. [HCV Treatment of Injecting Drug Users in the Czech Republic-Survey among Viral Hepatitis Treatment Centres]
    • Czech
    • Mravčík V. Léčba VHC u injekčních uživatelů drog v ČR-průzkum mezi centry pro léčbu virových hepatitid. [HCV Treatment of Injecting Drug Users in the Czech Republic-Survey among Viral Hepatitis Treatment Centres]. Adiktologie. 2012;12(1): 10-22. Czech.
    • (2012) Adiktologie. , vol.12 , Issue.1 , pp. 10-22
    • Mravčík, V.1
  • 69
    • 18444397492 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
    • Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8(1): 45-49.
    • (2002) Eur Addict Res. , vol.8 , Issue.1 , pp. 45-49
    • Dalgard, O.1    Bjoro, K.2    Hellum, K.3
  • 70
    • 84859164566 scopus 로고    scopus 로고
    • Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
    • Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2011;55(4):1058-1069.
    • (2011) Hepatology. , vol.55 , Issue.4 , pp. 1058-1069
    • Grebely, J.1    Pham, S.T.2    Matthews, G.V.3
  • 71
    • 0036829486 scopus 로고    scopus 로고
    • Prevention and treatment of hepatitis C in injection drug users
    • Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 Suppl 1):S210-S219.
    • (2002) Hepatology. , vol.36 , Issue.5 SUPPL. 1
    • Edlin, B.R.1
  • 72
    • 84873047820 scopus 로고    scopus 로고
    • Why is greater medication adherence associated with better outcomes
    • Hartz A, He T. Why is greater medication adherence associated with better outcomes. Emerg Themes Epidemiol. 2013;10(1):1.
    • (2013) Emerg Themes Epidemiol. , vol.10 , Issue.1 , pp. 1
    • Hartz, A.1    He, T.2
  • 73
    • 67449086883 scopus 로고    scopus 로고
    • Review article: Adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research
    • Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009;30(1):14-27.
    • (2009) Aliment Pharmacol Ther. , vol.30 , Issue.1 , pp. 14-27
    • Weiss, J.J.1    Brau, N.2    Stivala, A.3    Swan, T.4    Fishbein, D.5
  • 74
    • 79958807454 scopus 로고    scopus 로고
    • Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    • ATAHC Study Group
    • Grebely J, Matthews GV, Hellard M, et al; ATAHC Study Group. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76-85.
    • (2011) J Hepatol. , vol.55 , Issue.1 , pp. 76-85
    • Grebely, J.1    Matthews, G.V.2    Hellard, M.3
  • 75
    • 33144489685 scopus 로고    scopus 로고
    • Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes
    • Robaeys G, Van Vlierberghe H, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006;18(2):159-166.
    • (2006) Eur J Gastroenterol Hepatol. , vol.18 , Issue.2 , pp. 159-166
    • Robaeys, G.1    Van Vlierberghe, H.2    Mathei, C.3
  • 76
    • 77955466100 scopus 로고    scopus 로고
    • Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: Results of a prospective cohort study
    • Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22(9):1050-1057.
    • (2010) Eur J Gastroenterol Hepatol. , vol.22 , Issue.9 , pp. 1050-1057
    • Melin, P.1    Chousterman, M.2    Fontanges, T.3
  • 77
    • 36348986800 scopus 로고    scopus 로고
    • Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects
    • Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991-998.
    • (2007) Hepatology. , vol.46 , Issue.4 , pp. 991-998
    • Schaefer, M.1    Hinzpeter, A.2    Mohmand, A.3
  • 78
    • 70349754174 scopus 로고    scopus 로고
    • High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin
    • Gazdik F, Gazdikova K, Laktis K, et al. High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratisl Lek Listy. 2009;110(2):77-84.
    • (2009) Bratisl Lek Listy. , vol.110 , Issue.2 , pp. 77-84
    • Gazdik, F.1    Gazdikova, K.2    Laktis, K.3
  • 79
    • 77953024803 scopus 로고    scopus 로고
    • Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance
    • Schulte B, Schütt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109(1-3):248-251.
    • (2010) Drug Alcohol Depend. , vol.109 , Issue.1-3 , pp. 248-251
    • Schulte, B.1    Schütt, S.2    Brack, J.3
  • 80
    • 67651083226 scopus 로고    scopus 로고
    • Hepatitis C treatment for injection drug users: A review of the available evidence
    • Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561-573.
    • (2009) Clin Infect Dis. , vol.49 , Issue.4 , pp. 561-573
    • Hellard, M.1    Sacks-Davis, R.2    Gold, J.3
  • 81
    • 84874781548 scopus 로고    scopus 로고
    • Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis
    • Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2012;55(6):806-816.
    • (2012) Clin Infect Dis. , vol.55 , Issue.6 , pp. 806-816
    • Dimova, R.B.1    Zeremski, M.2    Jacobson, I.M.3    Hagan, H.4    Des Jarlais, D.C.5    Talal, A.H.6
  • 82
    • 72249093341 scopus 로고    scopus 로고
    • Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    • Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123-135.
    • (2010) Gastroenterology. , vol.138 , Issue.1 , pp. 123-135
    • Dore, G.J.1    Hellard, M.2    Matthews, G.V.3
  • 83
    • 34547942089 scopus 로고    scopus 로고
    • Adherence to hepatitis C treatment in recovering heroin users maintained on methadone
    • Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741-747.
    • (2007) Eur J Gastroenterol Hepatol. , vol.19 , Issue.9 , pp. 741-747
    • Sylvestre, D.L.1    Clements, B.J.2
  • 84
    • 20144388420 scopus 로고    scopus 로고
    • Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries
    • Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis. 2005;40 Suppl 5:373-378.
    • (2005) Clin Infect Dis. , vol.40 , Issue.SUPPL. 5 , pp. 373-378
    • Reimer, J.1    Schulte, B.2    Castells, X.3
  • 85
    • 84855215941 scopus 로고    scopus 로고
    • European Association of the Study of the Liver hepatitis C virus clinical practice guidelines
    • Calvaruso V, Craxi A. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8.
    • (2012) Liver Int. , vol.32 , Issue.SUPPL. 1 , pp. 2-8
    • Calvaruso, V.1    Craxi, A.2
  • 86
    • 84880966007 scopus 로고    scopus 로고
    • Recommendations for the management of hepatitis C virus infection among people who inject drugs
    • International Network on Hepatitis in Substance Users
    • Robaeys G, Grebely J, Mauss S, et al; International Network on Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129-S137.
    • (2013) Clin Infect Dis. , vol.57 , Issue.SUPPL. 2
    • Robaeys, G.1    Grebely, J.2    Mauss, S.3
  • 87
    • 0034956562 scopus 로고    scopus 로고
    • Treatment of hepatitis C infection in injection drug users
    • Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001;34(1): 188-193.
    • (2001) Hepatology. , vol.34 , Issue.1 , pp. 188-193
    • Backmund, M.1    Meyer, K.2    Von Zielonka, M.3    Eichenlaub, D.4
  • 88
    • 67149143393 scopus 로고    scopus 로고
    • Need-adapted HCV-treatment setting for injection drug users
    • Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet. 2009;373(9681):2090-2091.
    • (2009) Lancet. , vol.373 , Issue.9681 , pp. 2090-2091
    • Reimer, J.1    Haasen, C.2
  • 89
    • 34548481302 scopus 로고    scopus 로고
    • Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study
    • Nguyen OK, Dore GJ, Kaldor JM, Hellard ME. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. Int J Drug Policy. 2007;18(5): 447-451.
    • (2007) Int J Drug Policy. , vol.18 , Issue.5 , pp. 447-451
    • Nguyen, O.K.1    Dore, G.J.2    Kaldor, J.M.3    Hellard, M.E.4
  • 90
    • 78649243992 scopus 로고    scopus 로고
    • Uptake and delivery of C treatment in opiate substitution treatment: Perceptions of clients and health professionals
    • Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010;17(12): 839-844.
    • (2010) J Viral Hepat. , vol.17 , Issue.12 , pp. 839-844
    • Treloar, C.1    Newland, J.2    Rance, J.3    Hopwood, M.4
  • 91
    • 38949197759 scopus 로고    scopus 로고
    • Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service
    • Teasdale KE, Keren KM, Kiel A, Becker K. Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service. Drug Alcohol Rev. 2008;27(2):152-159.
    • (2008) Drug Alcohol Rev. , vol.27 , Issue.2 , pp. 152-159
    • Teasdale, K.E.1    Keren, K.M.2    Kiel, A.3    Becker, K.4
  • 92
    • 16844376913 scopus 로고    scopus 로고
    • Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities
    • Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis. 2005;40 Suppl 5:S339-S345.
    • (2005) Clin Infect Dis. , vol.40 , Issue.SUPPL. 5
    • Litwin, A.H.1    Soloway, I.2    Gourevitch, M.N.3
  • 93
    • 77955370219 scopus 로고    scopus 로고
    • Factors to improve the management of hepatitis C in drug users: An observational study in an addiction centre
    • pii261472
    • Moussalli J, Delaquaize H, Boubilley D, et al. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010:pii261472.
    • (2010) Gastroenterol Res Pract. 2010
    • Moussalli, J.1    Delaquaize, H.2    Boubilley, D.3
  • 94
    • 16844374761 scopus 로고    scopus 로고
    • Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection
    • Hagan H, Strauss SM, Astone JM, Des Jarlais DC. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis. 2005;40 Suppl 5:S297-S303.
    • (2005) Clin Infect Dis. , vol.40 , Issue.SUPPL. 5
    • Hagan, H.1    Strauss, S.M.2    Astone, J.M.3    Des Jarlais, D.C.4
  • 97
    • 0035913261 scopus 로고    scopus 로고
    • Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
    • Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345(3): 211-215.
    • (2001) N Engl J Med. , vol.345 , Issue.3 , pp. 211-215
    • Edlin, B.R.1    Seal, K.H.2    Lorvick, J.3
  • 98
    • 33845283877 scopus 로고    scopus 로고
    • Hepatitis C in Australia: Impact of a mass media campaign
    • Smith BJ, Bauman AE, Chen J, et al. Hepatitis C in Australia: impact of a mass media campaign. Am J Prev Med. 2006;31(6):492-498.
    • (2006) Am J Prev Med. , vol.31 , Issue.6 , pp. 492-498
    • Smith, B.J.1    Bauman, A.E.2    Chen, J.3
  • 99
    • 0028137673 scopus 로고
    • Syringe and needle exchange as HIV/AIDS prevention for injection drug users
    • Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115-120.
    • (1994) JAMA. , vol.271 , Issue.2 , pp. 115-120
    • Watters, J.K.1    Estilo, M.J.2    Clark, G.L.3    Lorvick, J.4
  • 100
    • 0032529426 scopus 로고    scopus 로고
    • Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992-1995
    • Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992-1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):505-511.
    • (1998) J Acquir Immune Defic Syndr Hum Retrovirol. , vol.18 , Issue.5 , pp. 505-511
    • Bluthenthal, R.N.1    Kral, A.H.2    Erringer, E.A.3    Edlin, B.R.4
  • 101
    • 0034119211 scopus 로고    scopus 로고
    • The effect of syringe exchange use on high-risk injection drug users: A cohort study
    • Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605-611.
    • (2000) AIDS. , vol.14 , Issue.5 , pp. 605-611
    • Bluthenthal, R.N.1    Kral, A.H.2    Gee, L.3    Erringer, E.A.4    Edlin, B.R.5
  • 102
    • 0038575483 scopus 로고    scopus 로고
    • Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
    • Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80-88.
    • (2003) Gastroenterology. , vol.125 , Issue.1 , pp. 80-88
    • Gerlach, J.T.1    Diepolder, H.M.2    Zachoval, R.3
  • 103
    • 33644501853 scopus 로고    scopus 로고
    • Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study
    • Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250-256.
    • (2006) Hepatology. , vol.43 , Issue.2 , pp. 250-256
    • Wiegand, J.1    Buggisch, P.2    Boecher, W.3
  • 104
    • 37049001443 scopus 로고    scopus 로고
    • Barriers associated with the treatment of hepatitis C virus infection among illicit drug users
    • Grebely J, Genoway KA, Raffa JD et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence. 2008;93;(1-2):141-147.
    • (2008) Drug and Alcohol Dependence. , vol.93 , Issue.1-2 , pp. 141-147
    • Grebely, J.1    Genoway, K.A.2    Raffa, J.D.3
  • 105
    • 69249227492 scopus 로고    scopus 로고
    • Hepatitis C treatment in patients with drug addiction: Clinical management of interferon-alpha-associated psychiatric side effects
    • Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev. 2008;(2):177-187.
    • (2008) Curr Drug Abuse Rev. , Issue.2 , pp. 177-187
    • Schaefer, M.1    Mauss, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.